Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Isofol Medical AB ( (SE:ISOFOL) ) has shared an update.
Isofol Medical AB has successfully completed a pre-IND meeting with the FDA for its drug candidate arfolitixorin, receiving positive feedback that validates its clinical development plan. This milestone supports Isofol’s strategy for the U.S. market and strengthens its position in the oncology sector, as the company continues its Phase Ib/II study to optimize treatment for metastatic colorectal cancer.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate aimed at enhancing the effectiveness of standard treatments for solid tumors, particularly in colorectal cancer, which is the third most common cancer globally. Isofol is listed on Nasdaq Stockholm.
Average Trading Volume: 996,477
Current Market Cap: SEK232M
See more insights into ISOFOL stock on TipRanks’ Stock Analysis page.